aibio
Listings ·
Ensysce gets Nasdaq bid price extension to February 2027
Nasdaq extended the Ensysce Biosciences bid price deadline to February 22, 2027, and said the company must meet initial listing criteria after its Cy Biopharma acquisition.
ENSC Ensysce Biosciences, Inc.
Ensysce Biosciences (ENSC) news ENSC delisting, offering and Nasdaq notice news
Latest Ensysce Biosciences news
- Financings
Ensysce completes Cy Biopharma acquisition with $38.6 million placements
Ensysce Biosciences said the Cy Biopharma acquisition closed on August 6, 2026, with private placement financings of $38.6 million and cash runway into late 2027.
- Mergers
Ensysce Biosciences buys Cy Biopharma, agrees to two-tranche private placement of Series C stock
Ensysce completed its acquisition of Cy Biopharma on August 5, 2026 and agreed to a Series C private placement of about $43 million in two tranches. After the deal, Cy's former holders would own about 73.86% of Ensysce on a fully diluted basis, and the second tranche depends on a clinical milestone.
- Company Updates
Ensysce chief operating officer Jeffrey Millard resigns
Ensysce Biosciences disclosed in an 8-K that Jeffrey Millard resigned as chief operating officer, effective July 10, 2026, with no reason or successor given.
- Listings
Ensysce receives Nasdaq notice on stockholders' equity requirement
Nasdaq said Ensysce Biosciences must submit a plan by July 6, 2026, to regain compliance with its $2.5 million stockholders' equity requirement, or face delisting.
- Company Updates
Ensysce reports first quarter 2026 results and starts strategic review
Ensysce Biosciences reported first quarter 2026 results, said its PF614-301 Phase 3 trial reached 50% of its interim enrollment target, and began a review of strategic alternatives.
- Financings
Ensysce Biosciences closes $2 million Series B preferred stock and warrant private placement
Ensysce Biosciences sold 2,000 shares of Series B preferred stock for $2 million on April 6, 2026, to 3i, LP. The deal comes with warrants for up to 8,727,273 common shares, all at $0.55, and the stated value of the preferred stock was raised from $1,100 to $1,200 a share.
- Company Updates
Ensysce director Curtis Rosebraugh resigns from board
Ensysce Biosciences said director Curtis Rosebraugh resigned effective April 1, 2026, and that he had served on the Nominating and Corporate Governance Committee.
What Ensysce Biosciences does
Ensysce Biosciences, Inc. is a clinical stage pharmaceutical company seeking to develop solutions for severe pain relief while reducing the potential for opioid misuse, abuse and overdose. Its platforms include the Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology, and the Multi-Pill Abuse Resistant (MPAR) platform, which combines TAAP prodrugs with nafamostat to limit bioavailability after co-ingestion of multiple doses. Its lead product candidate, PF614, is a TAAP oxycodone prodrug under development for acute or chronic pain. A Phase 1 single ascending dose trial in 64 healthy subjects showed that PF614 was well tolerated with no serious adverse events. The PF614-MPAR combination was granted Breakthrough Therapy designation by the FDA in January 2024. A second study, PF614-MPAR-102, designed to evaluate overdose protection across a range of dosages, began enrolling in December 2024. The company describes its primary focus as opioid pain products and opioid use disorder products, and says it has three clinical-stage product candidates.
| Product or program | What it is | Stage |
|---|---|---|
| PF614 | TAAP oxycodone prodrug for acute or chronic pain | clinical-stage |
| PF614-MPAR | PF614 combined with nafamostat for overdose protection | Breakthrough Therapy designation |
Ensysce Biosciences annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $5.1 million | $5.2 million |
| Research and development | $10.4 million | $7.2 million |
| Cash from operations | -$7.8 million | -$7.5 million |
| Cash and equivalents | $4.3 million | $3.5 million |
Questions about Ensysce Biosciences
Was Ensysce Biosciences delisted?
Our latest story on this, dated May 22, 2026: "Ensysce receives Nasdaq notice on stockholders' equity requirement". The story links the filing or release it is based on. Read the story.
Has Ensysce Biosciences raised money recently?
Our latest story on this, dated Aug 13, 2026: "Ensysce completes Cy Biopharma acquisition with $38.6 million placements". The story links the filing or release it is based on. Read the story.
Has Ensysce Biosciences received a Nasdaq deficiency notice?
Our latest story on this, dated May 22, 2026: "Ensysce receives Nasdaq notice on stockholders' equity requirement". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Ensysce Biosciences?
Ensysce Biosciences, Inc. trades under the ticker ENSC on NASDAQ.
Where is Ensysce Biosciences listed?
Ensysce Biosciences, Inc. is listed on NASDAQ.
What is the SEC CIK of Ensysce Biosciences?
The SEC Central Index Key (CIK) for Ensysce Biosciences, Inc. is 1716947. Its filings are on SEC EDGAR.
How many shares does Ensysce Biosciences have outstanding?
19,456,794 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-13.
Which country or territory is Ensysce Biosciences listed under?
Our directory records Ensysce Biosciences, Inc. under United States.
What does Ensysce Biosciences do?
Our directory classifies Ensysce Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Ensysce Biosciences?
The ISIN recorded for Ensysce Biosciences, Inc. is US2936025046.
Does aibio.space cover Ensysce Biosciences?
aibio.space lists Ensysce Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Ensysce Biosciences incorporated?
SEC records list its state or country of incorporation as DE.
What does Ensysce Biosciences develop?
Ensysce Biosciences, Inc. is a clinical stage pharmaceutical company seeking to develop solutions for severe pain relief while reducing the potential for opioid misuse, abuse and overdose. Its platforms include the Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology, and the Multi-Pill Abuse Resistant (MPAR) platform, which combines TAAP prodrugs with nafamostat to limit bioavailability after co-ingestion of multiple doses.
What is PF614 from Ensysce Biosciences?
PF614: TAAP oxycodone prodrug for acute or chronic pain Stage: clinical-stage.
What is PF614-MPAR from Ensysce Biosciences?
PF614-MPAR: PF614 combined with nafamostat for overdose protection Stage: Breakthrough Therapy designation.
Investor discussion: Ensysce Biosciences
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
- Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.01,3.02,3.03,5.02,5.03,7.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
- Distress
Reported a leadership departure tied to a disagreement or a restructuring. SEC Form 8-K (Items 5.02,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.02,5.03,8.01,9.01). Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Stock chart
SEC filings and registration
- SEC name
- Ensysce Biosciences, Inc.
- CIK
- 1716947
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- ENSC (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 7946 IVANHOE AVENUE, LA JOLLA, CA, 92037
- Phone
- (858) 263-4196
- Shares outstanding
- 19,456,794 as of 2026-08-12 (10-Q filed 2026-08-13)
- Former names
- Leisure Acquisition Corp.
Recent filings
Listing details
- Company
- Ensysce Biosciences, Inc.
- Ticker
- ENSC
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US2936025046
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction